Advanced MelanomaPhase 1/2REVERTNCT07040436
Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1
A Phase 1/2 study testing OPM-101 in people with Advanced Melanoma, run by Oncodesign Precision Medicine.
Trial summary
This is a phase 1b/2a study including a dose escalation part (Phase 1b) and an extension part (Phase 2a). Both parts will be open-label, multicenter study of OPM-101 combined with the anti-PD-1 pembrolizumab as per standard of care in patients with MM who have been receiving an anti-PD-1-based treatment and have shown… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Advanced Melanoma
- What is being tested?
- OPM-101
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 41 participants
- Where
- No sites listed yet
- Study dates
- Sep 2025to Dec 2027
- Phase
- Phase 1/2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Written informed consent provided prior to any study-related procedure.
- Histologically confirmed, unresectable or metastatic stage III or IV melanoma.
- At least one measurable lesion per RECIST v.1.1 criteria.
- Patients with a documented and confirmed Progressive Disease with an anti-PD-1-based treatment given alone or in combination (except combination with an anti-LAG-3 drug). Progressive disease will be determined by the PI based on the SITC v3.0 guidelines.
- Note: Patients who have been treated with a combination of nivolumab and ipilimumab will also be considered for study inclusion.
- Patients with no anti-PD-1-based treatment administration within 4 weeks (or 6 weeks for a treatment with pembrolizumab administered with a 400 mg q6w scheme) prior to study treatment initiation.
Show all 25Show fewer
- Patients accepting to undergo a fresh biopsy at baseline and after 12 weeks of treatment (for Phase 1b only).
- In case a fresh baseline biopsy collection would represent a medical risk for the patient, an archival biopsy could be used, after discussion with the Medical Monitor and the Principal Investigator (PI)
- If archival sample is unavailable, and the patient cannot provide a fresh tumour biopsy at baseline due to medical risk or inaccessibility, the patient may still be enrolled if agreed upon between the Investigator and the Sponsor.
- Male or female patients ≥18 years.
- Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.
- Estimated life expectancy ≥3 months.
- Adequate hematologic parameters and organ function defined by:
- white blood cell count ≥3,000/µL
- absolute neutrophil count ≥1,500/µL without support of filgrastim
- platelet count ≥75,000/µL
- haemoglobin (Hgb) ≥9 g/dL (criterion must be met without erythropoietin dependency and without packed red blood cell transfusion within last 2 weeks)
- calculated creatinine clearance ≥50 mL/min (Cockroft Gault formula)
- serum total bilirubin ≤1.5 x ULN (or ≤3.0 x ULN if documented Gilbert syndrome) analysed using vanadate method.
- AST and ALT ≤2.5 x ULN (or ≤5.0 x ULN if liver metastases)
- International normalized ratio (INR) ≤1.5 x ULN unless patient is receiving anticoagulant therapy if partial thromboplastin or activated partial thromboplastin time (aPTT) is within therapeutic range of intended use of anticoagulants
- Urinalysis negative for haematuria
- Females of childbearing potential must have confirmed negative pregnancy test prior to OPM-101 administration (daily oral dosing) and willing to use effective contraception during OPM-101 treatment and for at least 3 months after the last dose of OPM-101. Females considered of non-childbearing potential are post-menopausal women and women having undergone hysterectomy.
- Females with childbearing potential must not be breast feeding.
- Males must agree to use effective barrier contraception during OPM-101 treatment and for 90 days (a spermatogenesis cycle) after the last dose of OPM-101.
Who cannot join
- Diagnosis of primary uveal and/or ocular melanoma, as well as mucosal melanoma
- Active leptomeningeal disease or uncontrolled brain metastasis. Patients with equivocal findings or with confirmed brain metastases are eligible for enrolment provided they are asymptomatic without the need for corticosteroid treatment for at least 4 weeks prior to the first dose of study drug(s).
- Patients who have received any line of therapy with a BRAF inhibitor or MEK inhibitor in the advanced disease setting.
- Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment within the stated timeframes:
- 4 weeks for any anti-PD-1-based therapy (except for previous treatments with pembrolizumab administered with a 400 mg q6w scheme for which the duration should be 6 weeks)
- 4 weeks for radiation therapy
Show all 44Show fewer
- 2 weeks for limited field radiation for palliation
- 4 weeks or 5 half-lives (whichever is longer) for continuous or intermittent small molecule therapeutics or any other investigational agent, receiving study therapy or has participated in a study of an investigational agent and received study therapy, or used an investigational device. The participation in the follow-up Phase (i.e., receiving no study treatment) of a prior study is allowed.
- 6 weeks for cytotoxic agents with major delayed toxicities, such as nitrosoureas and mitomycin C
- History of severe or life-threatening immune-related (IR) AEs during a previous treatment with anti-PD-1
- IR-myocarditis
- Grade ≥3, IR- interstitial lung disease IR-renal toxicity.
- Grade 4 for IR-maculopapular rash, IR-diarrhoea and enterocolitis, IR-rheumatological toxicity, IR-neuro(muscular) toxicity, IR-hepatotoxicity
- Unrecovered CTCAE at time of screening
- Any patient unrecovered to a CTCAE grade ≤2 for patients who has been pre-treated with anti-PD-1 monotherapy
- Any patient unrecovered to a CTCAE grade ≤ 1 for patients who has been pre-treated with the combination of nivolumab plus ipilimumab
- Any of the following cardiovascular criteria:
- Cardiac chest pain, defined as moderate pain that limits instrumental activities of daily living, ≤28 days before the first dose of study drug(s)
- Symptomatic pulmonary embolism ≤28 days before the first dose of study drug(s)
- Any history of acute myocardial infarction ≤6 months before the first dose of study drug(s)
- Any history of heart failure meeting New York Heart Association Classification (NYHA) class III or IV ≤6 months before the first dose of study drug(s)
- Any event of ventricular arrhythmia ≥Grade 2 in severity ≤6 months before the first dose of study drug(s)
- Any history of cerebrovascular accident ≤6 months before the first dose of study drug(s)
- Uncontrolled hypertension: systolic pressure ≥160 mmHg or diastolic pressure ≥100 mmHg despite anti-hypertension medications ≤28 days before the first dose of study drug(s)
- Any episode of syncope or seizure ≤28 days before the first dose of study drug(s)
- Any condition that required systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤4 weeks before administration of study drug.
- Note: Patients who are currently or have previously been on any of the following steroid regimens are not excluded:
- Adrenal replacement steroid (dose ≤10 mg daily of prednisone or equivalent)
- Topical, ocular, intra-articular, intranasal, or inhalational corticosteroid with minimal systemic absorption
- Short course (≤7 days) of corticosteroid prescribed prophylactically, e.g., for contrast dye allergy, or for the treatment of a non-autoimmune condition, e.g., delayed-type hypersensitivity reaction caused by contact allergen
- Active infection requiring systemic therapy
- History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years
- Active autoimmune diseases or history of autoimmune diseases that may relapse. Patients with the following diseases are not excluded and may proceed to further screening:
- Controlled type 1 diabetes
- Hypothyroidism provided it is managed with hormone replacement therapy only
- Controlled celiac disease
- Skin diseases not requiring systemic treatment, e.g., vitiligo, psoriasis, alopecia
- Any other disease that is not expected to recur in the absence of external triggering factors
- Known history of Human Immunodeficiency Virus (HIV, HIV 1/2 antibodies), known active Hepatitis B, i.e., HBsAg positive or detectable HBV DNA, known active Hepatitis C, i.e., detectable HCV RNA (qualitative).
- Hypersensitivity to any excipients in OPM-101 formulation, i.e., lactose, cellulose, polyvinylpyrrolidone, magnesium stearate.
- Hypersensitivity to any excipients in the pembrolizumab formulation (L-histidine, L-histidine hydrochloride monohydrate, sucrose, polysorbate 80)
- Patients who received live vaccine within 30 days of planned start of the study therapy.
- History or current evidence of any condition, therapy, laboratory abnormality or psychiatric or substance abuse disorder that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- Patients who received homeopathy within 14 days of planned start of the study therapy.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: REVERT Study: A Phase 1b/2a Study to Assess the Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1
This is a phase 1b/2a study including a dose escalation part (Phase 1b) and an extension part (Phase 2a).
Both parts will be open-label, multicenter study of OPM-101 combined with the anti-PD-1 pembrolizumab as per standard of care in patients with MM who have been receiving an anti-PD-1-based treatment and have shown resistance to it, as defined by the Society for Immunotherapy of Cancer (SITC) criteria (Kluger, 2020). The objective of the study is to assess whether the addition of OPM-101 will resensitisze the tumour to the anti-PD-1-based treatment.
Read more
Potential patients will be screened for this study during the period between initial evidence of disease progression on anti-PD-1 treatment and the required radiographic confirmation of disease progression. The intent is to initiate treatment with OPM-101 once the suspicion of disease progression on anti-PD-1-based therapy is confirmed, and the patient has signed the study Information and Consent Form. No anti-PD-1-based treatment should be administered within 4 weeks prior to study treatment initiation.
In the dose escalation part (Phase 1b) of the study, two different doses of OPM-101 will be evaluated (75 mg bid and 150 mg bid) in combination with pembrolizumab. Patients will receive the dose and regimen of pembrolizumab, as per the authorised product SmPC, in sequential cohorts using a 3 + 3 design, escalating if 0 of 3 (or 1 of 6) patients experience a dose-limiting toxicity (DLT) during the first 6 weeks of treatment and not escalating if 2 of 6 patients experience a DLT.
The RP2D of OPM-101 for the second part of the study (Phase 2a) in combination with pembrolizumab will be based on the rate of DLTs, incidence and severity of Treatment-Related AEs (AEs) and SAEs, and frequency of dose holds, reductions and discontinuations.
A Data and Safety Monitoring Board (DSMB) will assess the safety criteria and make recommendations about dose escalation/de-escalation during the Phase 1b part, and on the RP2D to be used for further patients in the Phase 2a. The selection of the dose level for the Phase 2a will be based on safety and on preliminary PK/PD or even trends of efficacy. The DSMB will also review periodically the data during the Phase 2a and make recommendations about the continuation of the study.
The cohort expansion part (Phase 2a) of the study will be conducted once the Phase 1b is completed and a safe and tolerated dose (potentially 150 mg bid) has been determined. Patients will receive daily oral treatment with OPM-101, while taking pembrolizumab for at least 12 weeks, i.e., at the time of the radiographic assessment of the disease for the primary endpoint evaluation. Patients who show a treatment response with Disease Control (CR, PR or SD) at 12 weeks will continue treatment with [OPM-101 + pembrolizumab] up to 24 weeks, when the second radiographic disease assessment is performed.
- Conditions
- Advanced Melanoma
- Being tested
- OPM-101
- Keywords
- OPM-101, Melanoma, resistance, Anti-PD1, RIPK2, advanced, immuno-oncology, anti-PD1 refractory, pembrolizumab
- Medical subject headings
- Melanoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OPM-101Drug
OPM-101 will be administered in combination with an authorized regimen of Pembrolizumab.
Pembrolizumab will be administered by IV infusion either at a dose of 200 mg every 3 weeks or at a dose of 400 mg every 6 weeks, as per Principal Investigator's decision.
| Study group | Role | What they receive |
|---|---|---|
| OPM-101 (in combination with pembrolizumab) | Experimental | OPM-101 will be administered as hard gelatin capsules twice a day for 24 weeks. In the Phase 1b, 2 doses of OPM-101 will be considered: 75 mg bid and 150 mg bid. At the end of this Phase 1b, a recommended dose for Phase 2a will be determined. During the Phase 2a, the recommended dose of OPM-101 will be administered bid over 24 weeks.
OPM-101 will be administered in combination with authorized regimen of Pembrolizumab. Receives: Drug: OPM-101 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Determination of the recommended dose
In the phase 1b: the recommended dose for phase 2a will be based on the independent assessement of safety of OPM-101 by the DSMB
Measured: 6 weeks
Determination of the Disease Control Rate (DCR)
In phase 2a, Disease Control Rate defined as CR, PR or SD as per RECIST v.1.1 criteria
Measured: 12 weeks
Secondary outcomes (5)
Determination of the Disease Control Rate
In Phase 1b: Disease Control Rate (DCR= CR+PR+SD) per RECIST v.1.1 criteria.
Measured: 12 weeks
Determination of the Disease Control Rate
In Phase 1b and Phase 2a: Disease Control Rate (DCR= CR+PR+SD) per RECIST v.1.1 criteria.
Measured: 24 weeks
Determination of the objective response rate (ORR)
In the phase 1b and Phase 2a, the objective response rate (ORR = CR + PR) will be evaluated using RECIST v1.1 criteria
Measured: Week 12 and Week 24
Determination of the frequency of dose reduction, and discontinuations
In Phase 1b and Phase 2a
Measured: 24 weeks
Safety assessments
Phase 2a: determine the incidence and severity of adverse events (AEs) and serious adverse events (SAEs
Measured: 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jun 2025
- Study startSep 2025 (estimated)
- Primary completionSep 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced MelanomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Open label phase 1b/2a study
- Masking
- None (open label)
- Enrolment
- 41 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Oncodesign Precision Medicine
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07040436
- Sponsor's protocol ID
- OPM101-P2-01
- Acronym
- REVERT
- Status last verified
- Jun 2025
- First submitted
- 13 Jun 2025
- Last updated
- 27 Jun 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- REVERT Study: A Phase 1b/2a Study to Assess the Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1
- ClinicalTrials.gov ID
- NCT07040436
- Acronym / sponsor ID
- REVERT / OPM101-P2-01
- Conditions
- Advanced Melanoma
- Keywords
- OPM-101, Melanoma, resistance, Anti-PD1, RIPK2, advanced, immuno-oncology, anti-PD1 refractory
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 41 participants (estimated)
- Lead sponsor
- Oncodesign Precision MedicineIndustry (pharma, biotech, devices)
- Study start
- Sep 2025 (estimated)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 27 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a phase 1b/2a study including a dose escalation part (Phase 1b) and an extension part (Phase 2a).
Both parts will be open-label, multicenter study of OPM-101 combined with the anti-PD-1 pembrolizumab as per standard of care in patients with MM who have been receiving an anti-PD-1-based treatment and have shown resistance to it, as defined by the Society for Immunotherapy of Cancer (SITC) criteria (Kluger, 2020). The objective of the study is to assess whether the addition of OPM-101 will resensitisze the tumour to the anti-PD-1-based treatment.
Potential patients will be screened for this study during the period between initial evidence of disease progression on anti-PD-1 treatment and the required radiographic confirmation of disease progression. The intent is to initiate treatment with OPM-101 once the suspicion of disease progression on anti-PD-1-based therapy is confirmed, and the patient has signed the study Information and Consent Form. No anti-PD-1-based treatment should be administered within 4 weeks prior to study treatment initiation.
In the dose escalation part (Phase 1b) of the study, two different doses of OPM-101 will be evaluated (75 mg bid and 150 mg bid) in combination with pembrolizumab. Patients will receive the dose and regimen of pembrolizumab, as per the authorised product SmPC, in sequential cohorts using a 3 + 3 design, escalating if 0 of 3 (or 1 of 6) patients experience a dose-limiting toxicity (DLT) during the first 6 weeks of treatment and not escalating if 2 of 6 patients experience a DLT.
The RP2D of OPM-101 for the second part of the study (Phase 2a) in combination with pembrolizumab will be based on the rate of DLTs, incidence and severity of Treatment-Related AEs (AEs) and SAEs, and frequency of dose holds, reductions and discontinuations.
A Data and Safety Monitoring Board (DSMB) will assess the safety criteria and make recommendations about dose escalation/de-escalation during the Phase 1b part, and on the RP2D to be used for further patients in the Phase 2a. The selection of the dose level for the Phase 2a will be based on safety and on preliminary PK/PD or even trends of efficacy. The DSMB will also review periodically the data during the Phase 2a and make recommendations about the continuation of the study.
The cohort expansion part (Phase 2a) of the study will be conducted once the Phase 1b is completed and a safe and tolerated dose (potentially 150 mg bid) has been determined. Patients will receive daily oral treatment with OPM-101, while taking pembrolizumab for at least 12 weeks, i.e., at the time of the radiographic assessment of the disease for the primary endpoint evaluation. Patients who show a treatment response with Disease Control (CR, PR or SD) at 12 weeks will continue treatment with [OPM-101 + pembrolizumab] up to 24 weeks, when the second radiographic disease assessment is performed.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Open label phase 1b/2a study
| Arm | Type | Receives |
|---|---|---|
| OPM-101 (in combination with pembrolizumab) | Experimental | Drug: OPM-101OPM-101 will be administered as hard gelatin capsules twice a day for 24 weeks. In the Phase 1b, 2 doses of OPM-101 will be considered: 75 mg bid and 150 mg bid. At the end of this Phase 1b, a recommended dose for Phase 2a will be determined. During the Phase 2a, the recommended dose of OPM-101 will be administered bid over 24 weeks. OPM-101 will be administered in combination with authorized regimen of Pembrolizumab. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (25 listed)
- Written informed consent provided prior to any study-related procedure.
- Histologically confirmed, unresectable or metastatic stage III or IV melanoma.
- At least one measurable lesion per RECIST v.1.1 criteria.
- Patients with a documented and confirmed Progressive Disease with an anti-PD-1-based treatment given alone or in combination (except combination with an anti-LAG-3 drug). Progressive disease will be determined by the PI based on the SITC v3.0 guidelines.
- Note: Patients who have been treated with a combination of nivolumab and ipilimumab will also be considered for study inclusion.
Key exclusion criteria (44 listed)
- Diagnosis of primary uveal and/or ocular melanoma, as well as mucosal melanoma
- Active leptomeningeal disease or uncontrolled brain metastasis. Patients with equivocal findings or with confirmed brain metastases are eligible for enrolment provided they are asymptomatic without the need for corticosteroid treatment for at least 4 weeks prior to the first dose of study drug(s).
- Patients who have received any line of therapy with a BRAF inhibitor or MEK inhibitor in the advanced disease setting.
- Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment within the stated timeframes:
- History of severe or life-threatening immune-related (IR) AEs during a previous treatment with anti-PD-1
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OPM-101OPM-101 will be administered in combination with an authorized regimen of Pembrolizumab. Pembrolizumab will be administered by IV infusion either at a dose of 200 mg every 3 weeks or at a dose of 400 mg every 6 weeks, as per Principal Investigator's decision. | Drug | OPM-101 (in combination with pembrolizumab) |
Primary outcome
Determination of the recommended dose
Time frame: 6 weeks
In the phase 1b: the recommended dose for phase 2a will be based on the independent assessement of safety of OPM-101 by the DSMB
Determination of the Disease Control Rate (DCR)
Time frame: 12 weeks
In phase 2a, Disease Control Rate defined as CR, PR or SD as per RECIST v.1.1 criteria
5 secondary outcomes
Determination of the Disease Control Rate
Time frame: 12 weeks
Determination of the Disease Control Rate
Time frame: 24 weeks
Determination of the objective response rate (ORR)
Time frame: Week 12 and Week 24
Determination of the frequency of dose reduction, and discontinuations
Time frame: 24 weeks
Safety assessments
Time frame: 24 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jun 2025.
Related trials for Advanced Melanoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 1/2
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
Melanoma
RecruitingPhase 3
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Melanoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 2
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Metastatic Melanoma, Advanced Locoregional Melanoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing OPM-101 in people with Advanced Melanoma, run by Oncodesign Precision Medicine.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 25 inclusion and 44 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Bruno Robin, PharmD (+33 3 1045 1820, brobin@oncodesign.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Determination of the recommended dose (time frame: 6 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jun 2025.